DOD PRCRP Webinar  
Thursday, April 6, 2023  

Questions and Answers  
Dr. Donna Kimbark, DOD PRCRP Program Manager  

1. What are the funding opportunities for researchers located outside of the United States? Does the researcher’s location change anything in terms of eligibility and success rates for obtaining this type of funding?

PRCRP as part of CDMRP funds globally. You will need to initiate a sam.gov profile and receive a unique entity identifier if your organization has never been funded by the US government.

2. I have created a patient decision aid for osteosarcoma, Ewing sarcoma, and other bone cancer decisions. It will be released to the public and to institutions later this month. PCORI does not fund decision aids so I have external funding from the Osteosarcoma Collaborative. I would like to continue pilot testing this tool over time in a longitudinal study. Would the DOD fund this?

PRCRP has several open calls and I invite you to review each of them to see if they would be a good fit: https://cdmrp.health.mil/funding/prcrp.

3. Patient Reported Outcomes are lacking for long term outcomes with bone cancer patients. For example, we don’t know how many people with limb salvage surgery eventually make a decision for amputation. This is a frequent question posed by parents making the decision for their children. Does the DOD fund qualitative research for PROs?

PRCRP has several open calls and I invite you to review each of them to see if they would be a good fit: https://cdmrp.health.mil/funding/prcrp.

4. One question I have is whether rare cancers, like osteosarcoma, are eligible for these grants. The bolded sentence in Section II.A.1 of the Impact Award program announcement says they are prohibited but the next sentence seems to say they are not prohibited.

Rare cancers are allowed. Any cancer that is listed in the PRCRP topic area list for FY23 is allowed. Since Sarcoma is one of the PRCRP listed topic areas, it is allowed. Congress allows PRCRP to fund cancers in the list even though they may be rare by definition.

5. What is VHL?

Von Hippel-Lindau Syndrome
6. Are these available for enterprise or academics only?

Both

7. Can non-PI’s (i.e., program managers) have an ebrap account?

Yes

8. Is there an SBIR option for PRCRP?

No

9. Do recently published papers/under reviewing papers count as preliminary data?

Preliminary data submitted to the proposal is counted as preliminary data. If you refer to the unpublished data and it is not available to be evaluated, it would count as not being submitted (though reviewers may note that it was not submitted but referred to).

10. What about if we want to expand the pre-clinical data collection?

For preclinical data collection expansion, you would not be able to submit to Idea award, but you would to the Impact award.

11. Is the program also open for research in adult sarcomas?

Yes, we are open to adult sarcomas.

12. Can similar proposals be submitted to PRCRP and the Rare cancers program?

They can be. But only one will be funded if selected.

13. Is there any advice on how to pick to apply to PRCRP vs Rare Cancers?

Decide by the funding opportunity and dollar amount. Also look at the funding rates. You can find these on the website under the PI information paper on the webpages.

14. Is personnel composition of review panel provided to applicants?

Not until all review processes are completed. We do not permit interaction between reviewer and applicants.
15. Is it possible to request exclusion of a specific named panel member?

Anyone you think would need to be excluded should be listed as a COI.

16. Can you submit the same proposal for two different mechanisms (e.g., PRCRP for brain tumors and the same for the Rare tumor)?

You can submit to both the PRCRP and RCRP but only one will be allowed to be funded if selected.

17. Any suggestions for resubmitting the proposal submitted in the prior year with good review score?

Use your summary statement and answer all the weaknesses. Read the program announcement carefully since some elements may have changed.

18. For the fellow option of the career development award, would a single R01 disqualify you for that?

Yes

19. With cancers that are more common in pediatric patients, but initial clinical trials may need to be done in adults (e.g., sarcoma). Can we propose adult trials that are eventually applicable to pediatric patients?

Yes, with justification.

20. Are these solicitations open to businesses as well, or just academic researchers?

Yes

21. Are postdocs eligible to apply?

If postdocs are considered to have a faculty level appointment, they can submit to the Idea award.

22. Do we need prior experience in writing proposals?

No

23. Is it possible to collaborate with other PI and work on the idea?

Yes
24. If preliminary data is not required, how do they justify the candidate idea?

You should present a strong background and justification.

25. Securing funding for research is highly competitive. If there is one solid reason to select the applicant, what factors will the selector consider?

The selection factors are published in the funding opportunity.

26. What is the main aspect of the grant that the consumers are interested in?

Please review the impact section of the funding opportunity. But I cannot speak for all consumers.

27. Who are the consumers and how is their score incorporated in the overall score calculation?

Consumers are recruited on an annual basis and their scores are considered equally to other voting members on the peer review panels.

28. How is the overall evaluation score calculated from the average score?

It is not calculated but based on a scoring metric.

29. If my project focuses on pediatric renal tumors, should it be submitted to the pediatric, adolescent, and young adult cancers competition or to the kidney cancers competition?

It should be submitted to the Kidney Cancer Research Program.